KO

Kodiak Sciences IncNASDAQ KOD Stock Report

Last reporting period 30 Sep, 2023

Updated 18 Nov, 2024

Last price

Market cap $B

0.137

Micro

Exchange

XNAS - Nasdaq

KOD Stock Analysis

KO

Uncovered

Kodiak Sciences Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.137

Dividend yield

Shares outstanding

52.309 B

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Palo Alto, California and currently employs 105 full-time employees. The company went IPO on 2018-10-04. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.

View Section: Eyestock Rating